Tracy Moore Duarte
Psychiatric/Mental Health · Chester, VANPI 1679145981
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 436 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 31.8% of the total. Among psychiatric/mental health clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 436 payments — averaging $14.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Teva Pharmaceuticals USA, Inc.$733
- AbbVie$720
- Lundbeck LLC$624
- Otsuka America Pharmaceutical, Inc.$484
- Alkermes, Inc.$382
- plus $1K from 11 others
What the payments were for
- Food & beverage$6,42599%
- Education$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 130 | $2,060 |
| Teva Pharmaceuticals USA, Inc. | 67 | $733 |
| AbbVie | 69 | $720 |
| Lundbeck LLC | 59 | $624 |
| Otsuka America Pharmaceutical, Inc. | 16 | $484 |
| Alkermes, Inc. | 18 | $382 |
| E.r. Squibb & Sons, L.L.C. | 14 | $379 |
| Neurocrine Biosciences, Inc. | 23 | $341 |
| Johnson & Johnson | 7 | $194 |
| Axsome Therapeutics, Inc. | 7 | $126 |
| Sunovion Pharmaceuticals Inc. | 7 | $117 |
| Almatica Pharma LLC | 6 | $93 |
| Vanda Pharmaceuticals Inc. | 5 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $59 |
| Idorsia Pharmaceuticals US Inc | 2 | $47 |
| Noven Therapeutics, LLC | 1 | $19 |
| Janssen Scientific Affairs, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$443
- REXULTI$247
- INGREZZA$125
- COBENFY$119
- INVEGA SUSTENNA$110
How this compares
$6,484 in reported general payments places this provider in the 90th percentile of 1,003 psychiatric/mental health providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 284 | $432,799 |
| IngrezzaValbenazine Tosylate | 32 | $248,001 |
| CaplytaLumateperone Tosylate | 106 | $171,095 |
| VraylarCariprazine Hcl | 68 | $102,702 |
| Chlorpromazine Hcl | 135 | $62,834 |
| Austedo XrDeutetrabenazine | 17 | $60,362 |
| Invega SustennaPaliperidone Palmitate | 24 | $51,194 |
| Paliperidone ErPaliperidone | 175 | $43,498 |
| LybalviOlanzapine/Samidorphan Malate | 22 | $35,637 |
| Lurasidone Hcl | 124 | $21,918 |
| Divalproex Sodium ErDivalproex Sodium | 248 | $20,541 |
| Aripiprazole | 207 | $20,490 |
| TrintellixVortioxetine Hydrobromide | 30 | $18,635 |
| Olanzapine | 559 | $17,283 |
| Clozapine | 174 | $16,722 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $484 | $432,799284 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $341 | $248,00132 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,060 | $171,095106 claims |
| AbbVieVraylar | $720 | $102,70268 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $733 | $60,36217 claims |
| Johnson & JohnsonInvega Sustenna | $194 | $51,19424 claims |
| Alkermes, Inc.Lybalvi | $382 | $35,63722 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $59 | $18,63530 claims |
| Almatica Pharma LLCLoreev Xr | $93 | $11,66626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,003 psychiatric/mental health providers in Virginia.
Other psychiatric/mental health in Chester
- Latoya BraggChester$8K
- Justin RayChesapeake$127K
- Katia HallChesapeake$88K
- Christine GilmoreBedford$75K
- Sarah FaberNewport News$59K
- Kristine GarciaGlen Allen$46K
- Tonjanika BoydRichmond$40K
- Kirby PatmonRichmond$36K
- Juliana FroschAmherst$36K
- Derick ReedyNickelsville$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.